Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients

  • Authors:
    • Satoshi Hirase
    • Atsuro Saitoh
    • Tri Budi Hartomo
    • Aiko Kozaki
    • Tomoko Yanai
    • Daiichiro Hasegawa
    • Keiichiro Kawasaki
    • Yoshiyuki Kosaka
    • Masafumi Matsuo
    • Nobuyuki Yamamoto
    • Takeshi Mori
    • Akira Hayakawa
    • Kazumoto Iijima
    • Hisahide Nishio
    • Noriyuki Nishimura
  • View Affiliations

  • Published online on: June 7, 2016     https://doi.org/10.3892/ol.2016.4682
  • Pages: 1119-1123
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Neuroblastoma is an aggressive pediatric tumor accounting for ~15% of cancer-associated mortalities in children. Despite the current intensive therapy, >50% of high-risk patients experience tumor relapse or regrowth caused by the activation of minimal residual disease (MRD). Although several MRD detection protocols using various reverse transcription-quantitative polymerase chain reaction (RT‑qPCR) markers have been reported to evaluate the therapeutic response and disease status of neuroblastoma patients, their clinical significance remains elusive. The present study reports two high‑risk neuroblastoma patients, whose MRD was consecutively monitored using 11 RT-qPCR markers (CHRNA3, CRMP1, DBH, DCX, DDC, GABRB3, GAP43, ISL1, KIF1A, PHOX2B and TH) during their course of treatment. The two patients initially responded to the induction therapy and reached MRD‑negative status. The patients' MRD subsequently became positive with no elevation of their urinary homovanillic acid, urinary vanillylmandelic acid and serum neuron‑specific enolase levels at 13 or 19 weeks prior to the clinical diagnosis of tumor relapse or regrowth. The present cases highlight the possibility of consecutive MRD monitoring using 11 markers to enable an early detection of tumor relapse or regrowth in high‑risk neuroblastoma patients.
View Figures
View References

Related Articles

Journal Cover

August 2016
Volume 12 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Hirase, S., Saitoh, A., Hartomo, T.B., Kozaki, A., Yanai, T., Hasegawa, D. ... Nishimura, N. (2016). Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients. Oncology Letters, 12, 1119-1123. https://doi.org/10.3892/ol.2016.4682
MLA
Hirase, S., Saitoh, A., Hartomo, T. B., Kozaki, A., Yanai, T., Hasegawa, D., Kawasaki, K., Kosaka, Y., Matsuo, M., Yamamoto, N., Mori, T., Hayakawa, A., Iijima, K., Nishio, H., Nishimura, N."Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients". Oncology Letters 12.2 (2016): 1119-1123.
Chicago
Hirase, S., Saitoh, A., Hartomo, T. B., Kozaki, A., Yanai, T., Hasegawa, D., Kawasaki, K., Kosaka, Y., Matsuo, M., Yamamoto, N., Mori, T., Hayakawa, A., Iijima, K., Nishio, H., Nishimura, N."Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients". Oncology Letters 12, no. 2 (2016): 1119-1123. https://doi.org/10.3892/ol.2016.4682